Regulatory Pfizer, Arvinas join SERD club with Veppanu approval PharmaphorumArvinas and Pfizer's Veppanu is the first PROTAC - and third oral SERD for breast cancer - to be approved by the FDA.OncologyRead full story pharminent May 4, 2026 (Last updated: May 4, 2026) Pharmaphorum Arvinas and Pfizer’s Veppanu is the first PROTAC – and third oral SERD for breast cancer – to be approved by the FDA. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Novartis unveils North Carolina API plant as final piece of $23B US expansionNext: Novo Nordisk to launch Ozempic for type 2 diabetes in US Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
